Alkermes Makes Board Appointment
Alkermes plc., a global biopharma company focusing on the treatment of central nervous system diseases, has appointed Nancy Snyderman to its board of directors. Snyderman has more than 28 years of experience as a medical journalist, most recently at NBC News, where she was chief medical editor. Prior to her work in journalism, she was vice president of corporate communications at Johnson & Johnson. Snyderman is also a board certified otolaryngologist-head and neck surgeon, and a fellow of the American College of Surgeons.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Diffusion Pharmaceuticals and WPD Pharmaceuticals get new chief medical officers.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.